Literature DB >> 22684926

Progressive multifocal leukoencephalopathy following treatment with bendamustine and rituximab.

Sean Warsch1, Peter J Hosein, Michele I Morris, Uygar Teomete, Ronald Benveniste, Jennifer R Chapman, Izidore S Lossos.   

Abstract

A 66-year-old female developed progressive multifocal leukoencephalopathy (PML) 17 months after treatment with bendamustine and rituximab chemoimmunotherapy. During her evaluation for PML, she was found to have a CD4 count of 176 cells/μL (reference range 492-1740). The patient demonstrated spontaneous recovery of symptoms that occurred in parallel with recovery of the CD4 counts. While PML is associated with rituximab therapy, the timing and patients' clinical course are atypical, raising the possibility of a previously unreported association with bendamustine therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22684926     DOI： 10.1007/s12185-012-1118-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  25 in total

1.  Incidence of hepatitis B reactivation following Rituximab therapy.

Authors:  Amr Hanbali; Yasser Khaled
Journal:  Am J Hematol       Date:  2009-03       Impact factor: 10.047

2.  High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.

Authors:  Izidore S Lossos; Peter J Hosein; Daniel Morgensztern; Francine Coleman; Maricer P Escalón; Gerald E Byrne; Joseph D Rosenblatt; Gail R Walker
Journal:  Leuk Lymphoma       Date:  2010-03

3.  Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.

Authors:  Stephanie J Carter; Steven H Bernstein; Jonathan W Friedberg; Paul M Barr
Journal:  Leuk Res       Date:  2011-08-06       Impact factor: 3.156

4.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2005-01-24       Impact factor: 44.544

Review 5.  Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.

Authors:  Lorenzo M Leoni
Journal:  Semin Hematol       Date:  2011-04       Impact factor: 3.851

Review 6.  Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Authors:  Anjana Elefante; Myron S Czuczman
Journal:  Am J Health Syst Pharm       Date:  2010-05-01       Impact factor: 2.637

7.  Outcome of deferred initial therapy in mantle-cell lymphoma.

Authors:  Peter Martin; Amy Chadburn; Paul Christos; Karen Weil; Richard R Furman; Jia Ruan; Rebecca Elstrom; Ruben Niesvizky; Scott Ely; Maurizio Diliberto; Ari Melnick; Daniel M Knowles; Selina Chen-Kiang; Morton Coleman; John P Leonard
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

8.  Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

Authors:  John C Byrd; Kanti Rai; Bercedis L Peterson; Frederick R Appelbaum; Vicki A Morrison; Jonathan E Kolitz; Lois Shepherd; John D Hines; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2004-05-11       Impact factor: 22.113

9.  Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Authors:  Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

10.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Authors:  Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  4 in total

1.  [A rare cause of a progressive speech impairment].

Authors:  J G Heckmann; S Ernst; B Kempf; R Hebecker; T Reithmeier; C M Wendtner
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-07-28       Impact factor: 0.840

Review 2.  Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).

Authors:  Amir Khalili; Michael Craigie; Martina Donadoni; Ilker Kudret Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-27       Impact factor: 4.147

3.  Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.

Authors:  Michael A Lane; Vijay Renga; Andrew R Pachner; Jeffrey A Cohen
Journal:  Case Rep Neurol Med       Date:  2015-01-29

4.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.